Regional response leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations

Kan Yang, Kunhua Fan, Naoto Kurihara, Hiroharu Shinozaki, Basil Rigas, Leonard H. Augenlicht, Levy Kopelovich, Winfried Edelmann, Raju Kucherlapati, Martin Lipkin

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Sulindac and other NSAIDs have been widely studied as potential chemopreventive agents for colon cancer. Short-term studies have shown adenomatous polyps to regress in patients with familial adenomatous polyposis (FAP). In this study the effect of sulindac on cancer as an endpoint was evaluated in ApcMin mice, a preclinical model of FAP with an Apc mutation in codon 850 that leads to gastrointestinal adenomas and carcinomas. Three groups of mice were studied all of which were fed AIN-76A diet: one group was fed AIN-76A diet alone, a second group received sulindac 200 p.p.m. premixed in the diet and a third group received sulindac 180 p.p.m. added in drinking water. ApcMin mice were killed 9 weeks after feeding was initiated. Mice receiving sulindac developed fewer tumors in the intestine overall; the major decrease in tumor development after sulindac was seen in the small intestine regardless of route of administration. In the large intestine, however, sulindac significantly increased the incidence, multiplicity and volume of tumors in the colon of ApcMin mice, a regional response to sulindac differing from previous reports. Quantitative measurements of apoptosis, Bax and Bcl-xL protein expression in the ApcMin mice revealed the ratio of Bax/Bcl-xL expression and apoptosis increased in the small intestine but decreased in the cecum, consistent with the regional tumorigenesis observed after sulindac. These findings thus suggest involvement of Bax and apoptosis in tumors developing after sulindac treatment in this mouse model.

Original languageEnglish (US)
Pages (from-to)605-611
Number of pages7
JournalCarcinogenesis
Volume24
Issue number3
DOIs
StatePublished - Mar 1 2003

Fingerprint

Sulindac
Large Intestine
Small Intestine
Carcinogenesis
Mutation
Adenomatous Polyposis Coli
Apoptosis
Diet
Neoplasms
Adenomatous Polyps
Cecum
Non-Steroidal Anti-Inflammatory Agents
Tumor Burden
Codon
Drinking Water
Adenoma
Colonic Neoplasms
Intestines
Colon

ASJC Scopus subject areas

  • Cancer Research

Cite this

Regional response leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations. / Yang, Kan; Fan, Kunhua; Kurihara, Naoto; Shinozaki, Hiroharu; Rigas, Basil; Augenlicht, Leonard H.; Kopelovich, Levy; Edelmann, Winfried; Kucherlapati, Raju; Lipkin, Martin.

In: Carcinogenesis, Vol. 24, No. 3, 01.03.2003, p. 605-611.

Research output: Contribution to journalArticle

Yang, K, Fan, K, Kurihara, N, Shinozaki, H, Rigas, B, Augenlicht, LH, Kopelovich, L, Edelmann, W, Kucherlapati, R & Lipkin, M 2003, 'Regional response leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations', Carcinogenesis, vol. 24, no. 3, pp. 605-611. https://doi.org/10.1093/carcin/24.3.605
Yang, Kan ; Fan, Kunhua ; Kurihara, Naoto ; Shinozaki, Hiroharu ; Rigas, Basil ; Augenlicht, Leonard H. ; Kopelovich, Levy ; Edelmann, Winfried ; Kucherlapati, Raju ; Lipkin, Martin. / Regional response leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations. In: Carcinogenesis. 2003 ; Vol. 24, No. 3. pp. 605-611.
@article{e935efc8b72d43aa82793c727777d666,
title = "Regional response leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations",
abstract = "Sulindac and other NSAIDs have been widely studied as potential chemopreventive agents for colon cancer. Short-term studies have shown adenomatous polyps to regress in patients with familial adenomatous polyposis (FAP). In this study the effect of sulindac on cancer as an endpoint was evaluated in ApcMin mice, a preclinical model of FAP with an Apc mutation in codon 850 that leads to gastrointestinal adenomas and carcinomas. Three groups of mice were studied all of which were fed AIN-76A diet: one group was fed AIN-76A diet alone, a second group received sulindac 200 p.p.m. premixed in the diet and a third group received sulindac 180 p.p.m. added in drinking water. ApcMin mice were killed 9 weeks after feeding was initiated. Mice receiving sulindac developed fewer tumors in the intestine overall; the major decrease in tumor development after sulindac was seen in the small intestine regardless of route of administration. In the large intestine, however, sulindac significantly increased the incidence, multiplicity and volume of tumors in the colon of ApcMin mice, a regional response to sulindac differing from previous reports. Quantitative measurements of apoptosis, Bax and Bcl-xL protein expression in the ApcMin mice revealed the ratio of Bax/Bcl-xL expression and apoptosis increased in the small intestine but decreased in the cecum, consistent with the regional tumorigenesis observed after sulindac. These findings thus suggest involvement of Bax and apoptosis in tumors developing after sulindac treatment in this mouse model.",
author = "Kan Yang and Kunhua Fan and Naoto Kurihara and Hiroharu Shinozaki and Basil Rigas and Augenlicht, {Leonard H.} and Levy Kopelovich and Winfried Edelmann and Raju Kucherlapati and Martin Lipkin",
year = "2003",
month = "3",
day = "1",
doi = "10.1093/carcin/24.3.605",
language = "English (US)",
volume = "24",
pages = "605--611",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Regional response leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations

AU - Yang, Kan

AU - Fan, Kunhua

AU - Kurihara, Naoto

AU - Shinozaki, Hiroharu

AU - Rigas, Basil

AU - Augenlicht, Leonard H.

AU - Kopelovich, Levy

AU - Edelmann, Winfried

AU - Kucherlapati, Raju

AU - Lipkin, Martin

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Sulindac and other NSAIDs have been widely studied as potential chemopreventive agents for colon cancer. Short-term studies have shown adenomatous polyps to regress in patients with familial adenomatous polyposis (FAP). In this study the effect of sulindac on cancer as an endpoint was evaluated in ApcMin mice, a preclinical model of FAP with an Apc mutation in codon 850 that leads to gastrointestinal adenomas and carcinomas. Three groups of mice were studied all of which were fed AIN-76A diet: one group was fed AIN-76A diet alone, a second group received sulindac 200 p.p.m. premixed in the diet and a third group received sulindac 180 p.p.m. added in drinking water. ApcMin mice were killed 9 weeks after feeding was initiated. Mice receiving sulindac developed fewer tumors in the intestine overall; the major decrease in tumor development after sulindac was seen in the small intestine regardless of route of administration. In the large intestine, however, sulindac significantly increased the incidence, multiplicity and volume of tumors in the colon of ApcMin mice, a regional response to sulindac differing from previous reports. Quantitative measurements of apoptosis, Bax and Bcl-xL protein expression in the ApcMin mice revealed the ratio of Bax/Bcl-xL expression and apoptosis increased in the small intestine but decreased in the cecum, consistent with the regional tumorigenesis observed after sulindac. These findings thus suggest involvement of Bax and apoptosis in tumors developing after sulindac treatment in this mouse model.

AB - Sulindac and other NSAIDs have been widely studied as potential chemopreventive agents for colon cancer. Short-term studies have shown adenomatous polyps to regress in patients with familial adenomatous polyposis (FAP). In this study the effect of sulindac on cancer as an endpoint was evaluated in ApcMin mice, a preclinical model of FAP with an Apc mutation in codon 850 that leads to gastrointestinal adenomas and carcinomas. Three groups of mice were studied all of which were fed AIN-76A diet: one group was fed AIN-76A diet alone, a second group received sulindac 200 p.p.m. premixed in the diet and a third group received sulindac 180 p.p.m. added in drinking water. ApcMin mice were killed 9 weeks after feeding was initiated. Mice receiving sulindac developed fewer tumors in the intestine overall; the major decrease in tumor development after sulindac was seen in the small intestine regardless of route of administration. In the large intestine, however, sulindac significantly increased the incidence, multiplicity and volume of tumors in the colon of ApcMin mice, a regional response to sulindac differing from previous reports. Quantitative measurements of apoptosis, Bax and Bcl-xL protein expression in the ApcMin mice revealed the ratio of Bax/Bcl-xL expression and apoptosis increased in the small intestine but decreased in the cecum, consistent with the regional tumorigenesis observed after sulindac. These findings thus suggest involvement of Bax and apoptosis in tumors developing after sulindac treatment in this mouse model.

UR - http://www.scopus.com/inward/record.url?scp=0037360331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037360331&partnerID=8YFLogxK

U2 - 10.1093/carcin/24.3.605

DO - 10.1093/carcin/24.3.605

M3 - Article

VL - 24

SP - 605

EP - 611

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 3

ER -